TRAF7
TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
Overview
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.83, animal model 0.60, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Pleural Mesothelioma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
- 1 · What it is
TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
- 2 · What goes wrong in cancer
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators.
- 3 · How drugs use it
No product in this corpus aims at TRAF7 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:20456 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6Q0C0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000131653 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.54 (GraphQL API, CC0)); IntOGen TRAF7 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation. Plays a role in the phosphorylation of MAPK1 and/or MAPK3, probably via its interaction with MAP3K3. Negatively regulates RLR-mediated innate immunity by promoting 'Lys-48'-linked ubiquitination of TBK1 through its RING domain to inhibit the cellular antiviral response. Promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA leading to targeting these two proteins to lysosomal degradative pathways, reducing the transcriptional activity of NF-kappa-B. Location: Cytoplasmic vesicle; Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).
- Mesothelioma: IntOGen driver in 2 cohorts (PLMESO)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Pleural mesothelioma: IntOGen driver in 2 cohorts (PLMESO)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TRAF7" OR ABSTRACT:"TRAF7" OR TITLE:"TNF receptor associated factor 7" OR ABSTRACT:"TNF receptor associated factor 7" OR TITLE:"E3 ubiquitin-protein ligase TRAF7" OR ABSTRACT:"E3 ubiquitin-protein ligase TRAF7" OR TITLE:"RNF119" OR ABSTRACT:"RNF119" OR TITLE:"DKFZp586I021" OR ABSTRACT:"DKFZp586I021" OR TITLE:"MGC7807" OR ABSTRACT:"MGC7807") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRAF7, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFLG
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetNFKB2
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetCYP2C8
Shares Pleural mesothelioma, Mesothelioma, IntOGen, Melanoma.
- TargetLATS2
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetHLA-DQA1
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetPDZD2
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetPI4KA
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetSHTN1
Shares Pleural mesothelioma, Mesothelioma, IntOGen.